GlassScriptPhysician profile
Asim A Mohammed
NPI 1922285139
$117,745.37
in general payments reported to CMS, 2019-2025
20 companies · $386 in 2025
The $386 reported for 2025 was less than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $60K · 2020: $272 · 2021: $12K · 2022: $22K · 2023: $23K · 2024: $155 · 2025: $386.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $14K · Travel and Lodging: $4,121 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,585 · Food and Beverage: $1,403.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $14,400.00 |
| Travel and Lodging | $4,121.32 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,585.00 |
| Food and Beverage | $1,402.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $51,262.91 | 2019-2023 | Impella |
| Novartis Pharmaceuticals Corporation | $47,442.69 | 2019-2023 | |
| Abbott Laboratories | $7,837.65 | 2019-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit, 2nd Gen Centrimag Primary Console |
| Astrazeneca Pharmaceuticals LP | $6,583.10 | 2020-2023 | Farxiga |
| Merck Sharp & Dohme LLC | $3,567.71 | 2022-2023 | Verquvo |
| Medtronic Vascular, INC. | $288.44 | 2019 | |
| Impulse Dynamics (USA) INC. | $181.95 | 2022-2025 | Optimizer |
| United Therapeutics Corporation | $122.02 | 2019-2023 | Remodulin |
| Lexicon Pharmaceuticals, INC. | $121.14 | 2023 | Inpefa |
| Regeneron Healthcare Solutions, INC. | $47.61 | 2024-2025 | Dupixent |
| Alnylam Pharmaceuticals INC. | $44.10 | 2025 | Amvuttra |
| Boston Scientific Corporation | $39.95 | 2020-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $36.74 | 2020-2025 | Lifevest |
| Cvrx, INC. | $28.77 | 2025 | Barostim Neo System |
| Pfizer INC. | $28.12 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $25.67 | 2024 | |
| Livanova USA, INC. | $25.10 | 2022 | |
| Daiichi Sankyo INC. | $23.90 | 2023 | Injectafer |
| Actelion Pharmaceuticals US, INC. | $22.11 | 2021 | |
| Abbvie INC. | $15.69 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asim Mohammed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.